Condition: Barrett's Esophagus · Intestinal Metaplasia · Sponsor: E-DA Hospital
Detections of goblet cells and dysplasia are crucial for diagnosis and determining the surveillance program of Barrett's esophagus (BE). However, the optimal biopsy numbers and their yield rates of intestinal metaplasia (IM) and dysplasia are still uncertain, especially in Asia. The aim of this study was to determine the optimal biopsy protocol of BE.
This description comes directly from the study's public registry record.
Ying-Nan Tsai, M.D · 886-7-6150011 · littlepig9933@gmail.com
Wen-Lun Wang, Ph.D · 886-7-6150011 · warrengodr@gmail.com
Always discuss trial participation with your own doctor first.
| E-DA Hospital | Kaohsiung City, Taiwan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05818072